Two San Francisco Bay-area biotechs – Adverum Biotechnologies, Inc. and 4D Molecular Therapeutics Inc. – presented updated Phase II readouts on 17 July for their gene therapy candidates for wet age-related macular degeneration (AMD), with each company saying it plans to move its candidate into Phase III during 2025.
Key Takeaways
-
Competing biotechs Adverum and 4D Molecular Therapeutics reported Phase II data for their gene therapies that they hope will offer a treatment-burden reduction in wet AMD.
-
Both drugs are intended to compete with Eylea and reduce the need for frequent anti-VEGF therapy injections
Presenting at the American Society of Retinal Specialists meeting in Stockholm, Adverum called its candidate ixoberogene soroparvovec (ixo-vec) potentially best-in-class and tried to dampen prior worries about product safety, while 4DMT talked up the safety of its candidate 4D-150, which it called a potential “pipeline in a product.” (Also see "Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD" - Scrip, 8 February, 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
